ArticleClinical case reports2025
Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Uncommon clinical presentations and diagnostic difficulties of antiphospholipid syndrome associated withMedical mycology case reports · 2026Article
- Case of severe thrombocytopenia with recurrent extensive deep vein thrombosis due to antiphospholipid syndrome, management challenge.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe thrombocytopenia in secondary antiphospholipid syndrome (APS) presents a significant management challenge. This case highlights the complexity of managing APS-related thrombocytopenia, requiring a nuanced approach to balancing bleeding and thrombotic risks. Intravenous immunoglobulin, followed by a short course of steroids, successfully increased platelet counts without adverse bleeding or thrombotic events. Initiating therapeutic anticoagulation with Warfarin was delayed until platelet counts exceeded 50 × 10^3/μL, emphasizing the cautious approach required in such cases to mitigate thrombotic risks while avoiding bleeding complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.